Navigation Links
Research findings expected to ease treatment of low neutrophil counts in cancer patients
Date:3/10/2010

For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy.

"Cool," Sabrina told Sheri Spunt, M.D., an associate member of the St. Jude Department of Oncology, after hearing the news and breaking into what Sabrina called her "happy dance." Sabrina is battling rhabdomyosarcoma.

Spunt is Sabrina's doctor and lead author of a study expected to transform how children like Sabrina are treated for neutropenia. Neutropenia is the dangerous drop in white blood cells that leaves cancer patients at increased risk for infections and can delay chemotherapy. The work appears in the March 10 edition of the Journal of Clinical Oncology.

In a study of 44 young cancer patients, investigators reported that the drugs pegfilgrastim and filgrastim were similarly safe and effective at restoring a safe level of neutrophils following chemotherapy. But pegfilgrastim treatment required a single injection, while filgrastim involved daily injections for a week or longer. The trial was a multicenter, randomized, open-label study to evaluate the safety and efficacy of the two drugs as well as how they are used and metabolized in the body.

"This study will make a big impact on the quality of life for patients and their families," Spunt said.

Both drugs are synthetic growth factors designed to stimulate production of neutrophils. Neutrophils are made in the bone marrow and protect against bacterial and fungal infections. They are often short-term casualties of chemotherapy. Filgrastim has been widely used to speed neutrophil recovery. Pegfilgrastim was developed as a longer-acting version of filgrastim. It is approved for use in adults.

Although the study focused on patients with sarcomas such as rhabdomyosarcoma and Ewing sarcoma, Spunt said the results will likely change neutropenia treatment for all childhood cancer patients. The study's participants ranged in age from 28 days to 21 years.

"A large percentage of childhood cancer patients get growth factor support during their therapy," Spunt explained. "The injections are painful for patients and difficult for parents, especially the parents of young children who often need two adults to administer the drug daily. The burdens of therapy for them are considerable."

Sabrina, who did not participate in this study, said she became accustomed to the daily shots administered by her grandmother, Alice Spence. But Sabrina always held tight to her mother's hand when the time came. She was happy when the daily injections were replaced by a single shot.

In the study, researchers reported that after the first round of chemotherapy with vincristine, doxorubicin and cyclophosphamide, neutrophil levels started to rise in half the patients five days after treatment with pegfilgrastim, compared with six days for the filgrastim group. By the third round of chemotherapy, which followed additional treatment with ifosfamide and etoposide, half the patients in both groups were improving in seven days.

Both pegfilgrastim and filgrastim are made by Amgen, a California-based pharmaceutical company. Filgrastim is metabolized in the kidneys. Pegfilgrastim includes a polyethylene glycol tail and is broken down by neutrophils. As a result, pegfilgrastim levels drop as the patient's neutrophils climb.


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Related medicine news :

1. International Iridoid Research Council Announced
2. 2010 Recipient of Minority Scholar Award Will Conduct Clinical Research on Leukemia
3. 2010 recipient of Minority Scholar Award will conduct clinical research on leukemia
4. AdMeTech Praises Rep. Cummings for Introducing $650 Million Prostate Research Bill
5. National Event Addresses Breakthroughs in Crohn's & Colitis Research: National Expert & Researcher Answers Key Questions on Interactive Webcast/Teleconference
6. Research Indicates First Time Trade Show Attendees Unable to Select the Best Display Systems to Match their Budgets -- Alta Graphics Provides the Answers
7. Researcher presents risk-free treatment for low female sexual desire
8. Editorial: Eye cancer research becomes a collaborative pursuit
9. Novel program translates behavioral and social science research into treatments to reduce obesity
10. Exposure to BPA may cause permanent fertility defects, Yale researchers find
11. MRI finds tumors in second breast of women diagnosed with cancer in one breast, Mayo researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical ... in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the ... products in action, learn more about their chosen field and network with their colleagues. ...
(Date:2/12/2016)... Atlanta, GA (PRWEB) , ... February 12, 2016 ... ... and relationship-marketing firm announced that nominations have closed for the ISE Southeast Awards ... categories will be announced at the ISE® Southeast Executive Forum and Awards Gala ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Every winter, someone ... This winter the West Penn Burn Center, part of the Allegheny Health ... to bring you the “Space Heaters Need Space” campaign. , “Space ...
(Date:2/12/2016)... ... ... The Jones Agency, a family owned insurance company with offices serving Arlington, Dallas, ... with the Tarrant Area Food Bank in the hopes of alleviating hunger for nearby ... Tarrant County Food Bank offers hope and security to the one in six Texas ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young Asset Protection, a full ... of the latest charity campaign in their community enrichment program. Art Expression utilizes ... worthy cause are currently being accepted at: http://artexpressioninc.org/ . , Art Expression ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- The primary goal of this research is to ... usage of liquid biopsy. Key information the survey seeks ... of liquid biopsy adoption amidst future users - Predominantly ... - Sample inflow to conduct liquid biopsy tests - ... so on. - Correlation analysis of sample type and ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
(Date:2/11/2016)... Feb. 11, 2016 Potrero Medical, Inc., the developer ... announce the appointment of George M. Rapier, III , ... Antonio, TX , WellMed is one of the nation,s ... and HMO members in Texas and ... out of his own internal medicine practice, he has been ...
Breaking Medicine Technology: